Washington State Department of Agriculture
(WSDA)

A mostly new team at the DOH Medical Cannabis Program solicited feedback on potential revisions to rules on compliant products, testing, labeling, and logos.

A legislative briefing outlined expected topics in 2024; a policy and rules update touched on work groups, rulemaking, and staffing; the recently-hired director kept his “internal” focus.

After an update on social equity license applicants, board members heard encouragement, criticism, and questions about the program, among other comments, from the public.

Aside from a short rulemaking update, most of the meeting focused on the new agency research team, including outputs and external collaborations they had begun to develop.

The WSLCB board and staff would convene again this week, but the next formal cannabis rulemaking action by members was not expected until October 25th.

The board heard about implementation of legislation and possible request bills; social equity applications; lab authority transfer; plus updates on medical endorsements and hiring.

With DOE staff moving forward on cannabis lab accreditation rulemaking, they explained the expected timeline for draft rules and heard feedback about the costly implications for labs.

A congressional committee heard how lack of federal rulemaking on CBD and hemp products contributed to endangering consumers through sale of unsafe hemp-derived cannabinoid products. 

Lab participants would get a glimpse of rulemaking procedure at the Department of Ecology and the Cannabinoid Science Work Group planned to convene under the WSLCB Research Unit.

The board heard how an environmental pesticides investigation was nearing completion along with comments from the incoming agency director and plans for staff focus groups.